Naruto, Japan

Kazuyoshi Miyata




Average Co-Inventor Count = 7.3

ph-index = 5

Forward Citations = 127(Granted Patents)


Location History:

  • Naruto, JP (1994 - 2002)
  • Itano-gun, JP (2007 - 2010)
  • Tokushima, JP (2012)

Company Filing History:


Years Active: 1994-2012

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Kazuyoshi Miyata: Innovator in Disinfectant Technology

Introduction

Kazuyoshi Miyata, an accomplished inventor from Naruto, Japan, has made significant contributions to the field of disinfectant technology. With a total of 11 patents to his name, Miyata has focused on creating effective solutions that prioritize safety and efficiency.

Latest Patents

Miyata's latest innovations include patents for an aqueous solution of olanexidine and the method of preparing this solution. His disinfectant is designed to contain olanexidine at a concentration sufficient to exhibit a demonstrable bactericidal effect while minimizing side effects such as skin irritation. Specifically, his formulation consists of an aqueous solution that incorporates olanexidine along with at least an equimolar amount of gluconic acid, and intentionally avoids acids or salts other than gluconic acid.

Career Highlights

Throughout his career, Kazuyoshi Miyata has worked with notable companies in the pharmaceutical industry, including Otsuka Pharmaceutical Factory, Inc. and Otsuka Pharmaceutical Company, Limited. His experience in these organizations has helped him to refine his innovations in healthcare and hygiene products.

Collaborations

Miyata has also collaborated with prominent colleagues such as Yasuhide Inoue and Yoshihiko Tsuda, contributing to a dynamic and innovative working environment that fosters the development of groundbreaking solutions in the field.

Conclusion

Kazuyoshi Miyata exemplifies the spirit of innovation in the realm of disinfectants. His patents reflect a commitment to advancing safety and efficacy in healthcare solutions, significantly impacting both the pharmaceutical industry and public health standards.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…